Fiala

Peptide library › Infections

Enfuvirtide

Also known as Fuzeon, T-20

FDA-approved drugInfections

First HIV fusion inhibitor, a twice-daily injection for resistant HIV; discontinued in the US in 2025.

What people use it for

What Enfuvirtide does in the body

A 36-amino-acid peptide that stops HIV fusing with immune cells by blocking the virus's gp41 protein.

Strength of evidence

Strong: Phase 3 TORO trials in treatment-experienced patients.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2003. Its maker discontinued it in the US in February 2025 as newer treatments reduced the need.

How it's taken

Route: Injection under the skin, twice daily

How long it lasts (half-life): About 4 hours

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Enfuvirtide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Enfuvirtide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Infections